The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Sends Warning Letters to More Than 50 GLP 1 Compounders and Manufacturers Wilson Sonsini Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 Journal of Pharmaceutical Innovation Springer Nature Link On July 23 and July 23, 2026 from 8:00 am to 4:30 pm EST, the Food and Drug Administration, HHS, will be holding a public advisory meeting of the Pharmacy Compounding Advisory Committee in Silver FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News